Phase II, study to evaluate the safety of APX001 with Invasive mold infections caused by Aspergillus or rare mold
Clinical Trial Grant
Administered By
Medicine, Infectious Diseases
Awarded By
Amplyx Pharmaceuticals, Inc.
Start Date
July 2, 2020
End Date
April 18, 2023
Administered By
Medicine, Infectious Diseases
Awarded By
Amplyx Pharmaceuticals, Inc.
Start Date
July 2, 2020
End Date
April 18, 2023